Victory Capital Management Inc. Purchases 9,921 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE)

Victory Capital Management Inc. lifted its position in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 4.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 232,983 shares of the company's stock after purchasing an additional 9,921 shares during the quarter. Victory Capital Management Inc. owned about 0.52% of Apogee Therapeutics worth $8,704,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Swiss National Bank grew its position in Apogee Therapeutics by 17.5% during the fourth quarter. Swiss National Bank now owns 44,300 shares of the company's stock worth $2,007,000 after buying an additional 6,600 shares in the last quarter. Commonwealth Equity Services LLC bought a new stake in shares of Apogee Therapeutics during the 4th quarter valued at about $222,000. Teacher Retirement System of Texas grew its holdings in shares of Apogee Therapeutics by 38.2% during the fourth quarter. Teacher Retirement System of Texas now owns 6,689 shares of the company's stock worth $303,000 after purchasing an additional 1,848 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Apogee Therapeutics in the fourth quarter worth approximately $226,000. Finally, JPMorgan Chase & Co. increased its position in shares of Apogee Therapeutics by 26.1% in the fourth quarter. JPMorgan Chase & Co. now owns 37,255 shares of the company's stock worth $1,688,000 after purchasing an additional 7,700 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Stock Performance

APGE traded down $0.82 during midday trading on Friday, hitting $40.82. The stock had a trading volume of 600,248 shares, compared to its average volume of 1,298,459. Apogee Therapeutics Inc. has a 1 year low of $26.20 and a 1 year high of $63.50. The business has a fifty day moving average of $40.43 and a 200 day moving average of $38.28. The company has a market cap of $1.88 billion, a P/E ratio of -11.34 and a beta of 1.47.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.19) by $0.24. On average, equities research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

Insider Transactions at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 10,090 shares of the firm's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total transaction of $454,958.10. Following the transaction, the insider directly owned 238,998 shares of the company's stock, valued at approximately $10,776,419.82. This trade represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 15,540 shares of company stock worth $653,093 in the last ninety days. Corporate insiders own 42.77% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on APGE. BTIG Research lifted their target price on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Monday, July 7th. Guggenheim restated a "buy" rating and set a $116.00 price objective on shares of Apogee Therapeutics in a research report on Wednesday, July 2nd. Wedbush reaffirmed an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a report on Monday, July 7th. Finally, Citigroup reiterated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, July 7th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics presently has an average rating of "Buy" and a consensus target price of $99.00.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.